Padza Cancer Immunotherapy Solutions

Established in 2016 in Iran, Padza is a knowledge-based organization committed to advancing cancer immunotherapy through innovative antibody production and cutting-edge laboratory services. Our mission is to revolutionize cancer research, diagnosis, and treatment by leveraging bioinformatics, biochemical expertise, and state-of-the-art technologies.

  • Leadership in Antibody Innovation
    Production of over 80 monoclonal and polyclonal antibodies, including enzyme- and fluorescence-conjugated products for diagnostic and therapeutic applications.
  • Targeted Cancer Immunotherapy
    Pioneering solutions for cancer stem cells, metastasis, drug resistance, relapses, and treatment failures.
  • Advanced Non-Invasive Diagnostics
    Expertise in molecular techniques such as PCR for early cancer detection and monitoring therapeutic outcomes.
  • Knowledge Localization
    Fully domestic production of antibodies and early cancer detection methods, ensuring cost-effective and high-quality solutions.
  • Research-Driven Development
    Focused on cancer stem cell research, preclinical testing, and humanization of murine antibodies for enhanced clinical efficacy.

Our Expertise and Vision

From producing pure monoclonal and polyclonal antibodies to offering comprehensive lab services, we tackle the complexities of cancer therapy, including metastasis, relapse, drug resistance, and treatment failures. Our commitment ensures accessible, affordable solutions tailored to both national and global needs.

Key Innovations

  • Antigen Design and Manufacturing

    Leveraging advanced bioinformatics and biochemical techniques to produce high-precision antigens.

  • Localized Antibody Production

    Fully domestic production ensures affordable, high-quality solutions for research and healthcare.

  • Hybridoma Bank

    Housing 200 hybridomas producing antibodies against 230 distinct antigens, with over 80 commercially available products.

  • Early Cancer Detection

    Developing localized, cutting-edge techniques for early cancer diagnosis.

  • Preclinical Research

    Validating antibody efficacy through in vivo studies and humanizing mouse-derived antibodies for clinical applications.

  • Comprehensive Lab Services

    Supporting cancer researchers with flow cytometry, cell culture, apoptosis tests, ELISA, and antigen/antibody analysis.

Padza Antibody Development Timeline

2024 and Beyond: Ongoing Innovations

Continuously advancing targeted cancer immunotherapy and diagnostics. Housing over 200 hybridoma cell lines and producing antibodies for cancer-specific markers.

2016: Foundation of Padza

Established a local hub for antibody production and cancer research. Establishment of Padza to bridge academia and biotechnology to advance cancer therapy.

2017-2018

Development of non-invasive diagnostic methods for cancer detection.

2019: COVID-19 Antibody Production

Rapid response to the pandemic with diagnostic antibodies. Expansion into diagnostic and therapeutic antibody production for COVID-19.

2002: Cell Research

Explored cancer stem cell markers in collaboration with Karolinska Institute. Collaboration with Karolinska Institute and Avicenna Research Institute to explore cancer stem cell (CSC) theories.

2013

Research on chronic lymphocytic leukemia (CLL) using markers such as ROR1, PRELP, Opticin, and Fibromodulin.

2014

Production of antibodies targeting these markers at Avicenna Institute, with results published in leading journals.

Trusted by Leading Institutions

We proudly collaborate with prominent academic and research centers, including:

    • Iran University of Medical Sciences
    • Tehran University of Medical Sciences
    • Shahid Beheshti University
    • Pasteur Institute
    • Royan Cancer Research Institutes
    • Ibn Sina Research Institute
    • And others
tehran--university-of-medical-science
tehran--university-of-medical-science-and-health-services
shahr-kord-university-of-medical-science
shahid-beheshti--university-of-medical-science
royan-cancer-research-institutes
iran-pasteur-institute
"I became acquainted with Padza Company and its products through the recommendation of professors in the field of immunotherapy. I recommend its good support, good employee ethics, and suitable and quality products to researchers."



Ali Reza Shokoohifar Immunotherapy Specialist
Birjand University of Medical Sciences
"I needed CD133 and CD67 antibodies for part of my PhD project. Given the high price and difficulty in accessing foreign antibodies, I contacted Padza. They were easy and quick to obtain, and Padza's experienced staff answered my questions. I recommend Padza's quality, affordable products, and excellent support to everyone."
Jogn Doe PhD student in Molecular Medicine
Kurdistan University of Medical Sciences

Why Choose Padza?

Our commitment to advancing cancer immunotherapy and diagnostics has earned the trust of universities, pharmaceutical companies, and medical research institutions worldwide. Here’s why Padza is your trusted partner in cancer research and diagnostics:

  • Trusted Expertise

    • Mission-Driven Innovation: Pioneering advancements in diagnostics and cancer therapy to transform patient outcomes. • Collaborative Partnerships: Trusted by 50+ research institutions for reliable results and breakthrough discoveries.

  • Cutting-Edge Research Capabilities

    • Innovative Immunotherapy Solutions: Driving advancements in cancer treatments and research. • Comprehensive Lab Services: Supporting diagnostics and treatments with precision and care.

  • Professional Excellence

    • Experienced Team: Delivering accurate, actionable results tailored to global standards. • 10+ Years of Research Excellence: A legacy of innovation and quality.

  • Affordable Quality

    • High-Quality Products: 80+ locally produced antibodies and 200+ hybridoma cell lines. • Globally Competitive Standards: Affordable solutions without compromising quality.

  • Advanced Lab Services

    • Flow Cytometry, ELISA Testing, Microscopic Imaging, and more.

A Word from Our Founder

Dr. Hodjat Rabbani is a pioneer in targeted cancer immunotherapy and diagnostic innovation, he integrates his expertise in antibody development with innovative diagnostic strategies to tackle complex challenges in oncology. His groundbreaking contributions have transformed research outcomes and paved the way for novel cancer treatments.

Dr. Hodjat Rabbani - Portfolio

“To address the challenges in experimental sciences, we must embrace dissent and bold thinking. At Padza, we aim to redefine cancer treatment by integrating local expertise with global standards, ensuring innovative and affordable solutions for all. From the start, our goal has been to push the boundaries of knowledge to create meaningful change in the fight against cancer.”

Dr. Hodjat Rabbani,

Senior Scientific Director of Padza

Scroll to Top